NGS + IHC Whole Exome Sequencing & PD-L1 (22C3) Package: Selecting the Right Patient Population

Overview

The combined whole exome sequencing and PD-L1 (22C3) immunohistochemistry package exists to answer a single commercial question: which patients are most likely to benefit from a given targeted or immune-based therapy. By pairing genomic breadth with a standardized PD-L1 readout, the package defines biomarker-selected populations rather than treating oncology as one undifferentiated market. For B2B providers, this shifts the sale from a generic sequencing service to a decision-support product. The population lens is what makes the test relevant to reimbursement and trial enrollment alike.

How It Works

Whole exome sequencing reads the protein-coding region of the tumor genome to surface mutations, copy-number changes and signals such as tumor mutation burden. In parallel, the PD-L1 (22C3) assay stains formalin-fixed tissue and scores the proportion of tumor cells expressing the PD-L1 protein. The two outputs are reported together so a clinician can match a patient to therapy based on both genomic and immune-microenvironment features. Standardized 22C3 scoring keeps the result comparable across pathology sites.

Indications

The package is intended for qualified molecular pathology and oncology settings evaluating advanced cancer patients for biomarker-guided therapy. It supports therapy selection, clinical-trial stratification and second-opinion genomic review. Testing requires adequate tumor tissue and a verified pre-analytical chain. Results must be interpreted by specialists alongside imaging and clinical history, and the service is not a stand-alone diagnostic verdict.

Dosage & Administration

There is no dosage; the specimen is dosed by the laboratory's validated protocol. A pathology lab submits qualified tumor tissue, and the provider performs sequencing and IHC following accredited procedures. Turnaround depends on sample quality and queue position, and reports are released only after internal quality control passes. Laboratories should track lot and reagent calibration to keep the 22C3 scoring consistent across cases.

Storage & Sourcing

Source the package from a provider holding relevant laboratory accreditation and a documented validation dossier for both the sequencing and IHC components. Confirm that tissue-handling and transport requirements are met before collection to avoid pre-analytical failure. For distributors, emphasize the integrated report and the accreditation behind it, since procurement committees weigh evidence and turnaround as much as price.

FAQ

Q: Why combine whole exome sequencing with PD-L1 22C3 in one package? A: Sequencing reveals genomic targets while the 22C3 score reflects immune eligibility, so together they define a biomarker-selected population for both targeted and immune therapies.

Q: Which patients are the package most useful for? A: Advanced cancer patients being evaluated for biomarker-guided therapy or trial enrollment, where tissue quantity allows both genomic and IHC analysis.

Q: What accreditation should a distributor verify? A: Confirm the provider holds relevant molecular-laboratory accreditation and a documented validation dossier covering both the sequencing and the 22C3 IHC components.